Gsk Plc Revenue Growth Rates (GSK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Gsk Plc  (NYSE: GSK)
 

GSK's Revenue Growth by Quarter and Year

Gsk Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GSK Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 43,093.89
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 43,093.89

GSKs Annual Revenue
Gsk Plc's Revenue in the fiscal year 2025 $ 32,667.00 millions
Gsk Plc's Revenue in the fiscal year 2024 $ 31,376.00 millions
Gsk Plc's Revenue in the fiscal year 2023 $ 37,727.90 millions
Gsk Plc's Revenue in the fiscal year 2022 $ 29,324.00 millions
Gsk Plc's Revenue in the fiscal year 2021 $ 34,114.00 millions




GSK Revenue fourth quarter 2025 Y/Y Growth Comment
Gsk Plc achieved in the fourth quarter 2025, above Company average Revenue growth of 37.35% year on year, to $ 43,093.89 millions.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 70 other companies have achieved higher Revenue growth. While Gsk Plc' s Revenue rise of 37.35% ranks overall at the positon no. 1611 in the fourth quarter 2025.


GSK Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 37.35 % 7 % -14.04 % 0.04 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   37.35 % 7 % -14.04 % -

Financial Statements
Gsk Plc's fourth quarter 2025 Revenue $ 43,093.89 millions GSK's Income Statement
Gsk Plc's fourth quarter 2024 Revenue $ 31,376.00 millions Quarterly GSK's Income Statement


GSK Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   37.35 % 7 % -14.04 % -


Back to GSK Growth rate Comparisons >> Back to GSK Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #71
Healthcare Sector #222
Overall #1611

Revenue Y/Y Growth Statistics
High Average Low
9.52 % -0.86 % -14.04 %
(Dec 31 2019)   (Dec 31 2022)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #71
Healthcare Sector #222
Overall #1611
Revenue Y/Y Growth Statistics
High Average Low
9.52 % -0.86 % -14.04 %
(Dec 31 2019)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Gsk Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GSK's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GSK's IV. Quarter Q/Q Revenue Comment


Gsk Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 32,667.00 $ 31,376.00 $ 37,727.90 $ 29,324.00 $ 34,114.00
Y / Y Revenue Growth (TTM) 4.11 % -16.84 % 28.66 % -14.04 % 0.04 %
Year on Year Revenue Growth Overall Ranking # 1907 # 0 # 2889 # 0 # 0
Seqeuential Revenue Change (TTM) 4.11 % -16.84 % 28.66 % -14.04 % 0.04 %
Seq. Revenue Growth (TTM) Overall Ranking # 1907 # 0 # 2880 # 0 # 0


Cumulative Revenue growth Comment
Gsk Plc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 4.11% year on year, to $ 32,667 millions if the fiscal year would have ended in Dec 31 2025.
Gsk Plc's trailing twelve months Revenue growth was higher than company's average 1.28% and higher than -16.84% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 4.11 % increase from $31376 millions in the period from Dec 31 2024 to Dec 31 2021.

In the Healthcare sector 297 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1907.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 298
Overall # 1907

Revenue TTM Y/Y Growth Statistics
High Average Low
9.52 %
 1.28 %
-14.04 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 298
S&P 500 # 1907
Cumulative Revenue growth Comment
Gsk Plc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 4.11% year on year, to $ 32,667 millions if the fiscal year would have ended in Dec 31 2025.
Gsk Plc's trailing twelve months Revenue growth was higher than company's average 1.28% and higher than -16.84% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 4.11 % increase from $31376 millions in the period from Dec 31 2024 to Dec 31 2021.

In the Healthcare sector 297 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1907.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 298
Overall # 1907

Revenue TTM Y/Y Growth Statistics
High Average Low
9.52 %
1.28 %
-14.04 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 298
S&P 500 # 1907




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GSK's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Axsome Therapeutics Inc 65.03%$ 65.030 millions
Kiniksa Pharmaceuticals International Plc64.95%$ 64.953 millions
Precision Optics Corporation Inc 62.76%$ 62.757 millions
Organigram Global Inc 62.15%$ 62.151 millions
Cardiff Oncology Inc 62.00%$ 62.000 millions
Beta Bionics Inc 61.17%$ 61.174 millions
Catheter Precision Inc 59.73%$ 59.732 millions
Euda Health Holdings Limited59.29%$ 59.292 millions
Xoma Royalty Corporation57.87%$ 57.872 millions
Immuron Limited55.99%$ 55.993 millions
Ideaya Biosciences Inc 55.37%$ 55.371 millions
Urogen Pharma Ltd 54.03%$ 54.028 millions
The Pennant Group Inc 53.17%$ 53.168 millions
Halozyme Therapeutics Inc 51.60%$ 51.596 millions
Nephros Inc 51.08%$ 51.084 millions
Adaptive Biotechnologies Corporation51.04%$ 51.038 millions
Mirum Pharmaceuticals Inc 49.81%$ 49.810 millions
Ascendis Pharma A49.14%$ 49.137 millions
Hyperfine Inc 48.82%$ 48.824 millions
Intelligent Bio Solutions Inc 47.62%$ 47.619 millions
Gossamer Bio Inc 47.13%$ 47.127 millions
Electrocore Inc 46.11%$ 46.111 millions
Mannkind Corporation45.82%$ 45.820 millions
Hologic Inc44.84%$ 44.836 millions
Ensysce Biosciences Inc 44.39%$ 44.389 millions
Profound Medical Corp 43.13%$ 43.127 millions
Regenxbio Inc 43.00%$ 43.005 millions
Xeris Biopharma Holdings Inc 42.78%$ 42.776 millions
Eli Lilly And Company42.56%$ 42.557 millions
Edwards Lifesciences Corporation42.48%$ 42.484 millions


About Gsk Plc Revenue Growth Rates (GSK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Gsk Plc (CIK 1131399).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001131399-26-000004
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Gsk Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.